Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers

被引：0
|
作者：
Lee, Jaeyop [1 ]
Ku, Geoffrey [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10065 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2024年 / 38卷 / 03期
关键词：
HER2; Esophagogastric cancer; Trastuzumab; Antibody drug conjugate; Immune modulation; Immunotherapy; Targeted therapy; ANTIBODY-DRUG CONJUGATE; GASTROESOPHAGEAL JUNCTION CANCER; GASTRIC-CANCER; TRASTUZUMAB DERUXTECAN; ADVANCED BREAST; HER2; STATUS; SINGLE-ARM; OPEN-LABEL; LAPATINIB; COMBINATION;
D O I：
10.1016/j.hoc.2024.02.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：585 / 598
页数：14
相关论文
共 50 条
  • [31] Re: Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor-targeted therapy - Responses
    Veronesi, Umberto
    Bonanni, Bernardo
    Decensi, Andrea
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (21) : 1644 - 1645
  • [32] Advances in endocrine and targeted therapy for hormone-receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Shen Le-Sang
    Jin Xiao-Yan
    Wang Xu-Meng
    Tou Lai-Zhen
    Huang Jian
    中华医学杂志英文版, 2020, 133 (09) : 1099 - 1108
  • [33] The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer
    Li, Huan
    Zhai, Qing
    Yu, Bo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S218 - S223
  • [34] PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
    Majewski, Ian J.
    Nuciforo, Paolo
    Mittempergher, Lorenza
    Bosma, Astrid J.
    Eidtmann, Holger
    Holmes, Eileen
    Sotiriou, Christos
    Fumagalli, Debora
    Jimenez, Jose
    Aura, Claudia
    Prudkin, Ludmila
    Carmen Diaz-Delgado, Maria
    de la Pena, Lorena
    Loi, Sherene
    Ellis, Catherine
    Schultz, Nikolaus
    de Azambuja, Evandro
    Harbeck, Nadia
    Piccart-Gebhart, Martine
    Bernards, Rene
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1334 - 1339
  • [35] Maximizing Human Epidermal Growth Factor Receptor 2 Inhibition: A New Oncologic Paradigm in the Era of Targeted Therapy
    Olson, Erin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1712 - 1714
  • [36] Human epidermal growth factor receptor-2 in oesophageal cancers:An observational study
    Hazem Al-Momani
    Rachel Barnes
    Ahmed El-Hadi
    Rachit Shah
    Wyn G Lewis
    Paul Edwards
    World Journal of Gastroenterology, 2012, (44) : 6447 - 6451
  • [37] Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
    Younes, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 923 - 923
  • [38] Human epidermal growth factor receptor-2 in oesophageal cancers: An observational study
    Al-Momani, Hazem
    Barnes, Rachel
    El-Hadi, Ahmed
    Shah, Rachit
    Lewis, Wyn G.
    Edwards, Paul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (44) : 6447 - 6451
  • [39] EXCESS HEALTH CARE COSTS AMONG ELDERLY BREAST CANCER PATIENTS, BY RECEIPT OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-TARGETED THERAPY: AN ANALYSIS OF SER-MEDICARE DATA
    Hao, Y.
    Lang, K.
    Huang, H.
    Lin, I
    Rogerio, J. W.
    Menzin, J.
    VALUE IN HEALTH, 2014, 17 (03) : A77 - A77
  • [40] Vascular Endothelial Growth Factor Receptor 2-Targeted Chemoprevention of Murine Lung Tumors
    Karoor, Vijaya
    Le, Mysan
    Merrick, Daniel
    Dempsey, Edward C.
    Miller, York E.
    CANCER PREVENTION RESEARCH, 2010, 3 (09) : 1141 - 1147
12345